☆ 4.7 Article

Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function?

DIABETES (2010)

Get Full Text
Add to Collection

Journal

DIABETES
Volume 59, Issue 5, Pages 1117-1125

Publisher

AMER DIABETES ASSOC
DOI: 10.2337/db09-1899

Keywords

-

Categories

Endocrinology & Metabolism

Funding

  1. Novo Nordisk
  2. Eli Lilly
  3. Merck Sharp Dohme
  4. Novartis
  5. sanofi-aventis
  6. AstraZeneca
  7. Bayer Vital Pharma
  8. Eli Lilly & Co. Indianapolis
  9. Menarini/Berlin-Chemie

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.